The global transdermal (percutaneous) drug delivery systems market is expected to register a healthy CAGR over the forecast period. The market held a market value of USD 5,400.2 million in 2017 and is projected to grow at a CAGR of 4.6% during the forecast period from 2018 to 2023. Transdermal drug delivery system (TDDS) delivers drugs through the skin to systemic circulation at a predetermined rate and maintain the effective concentrations clinically over an extended period. TDDS also called as patches are dosage forms that deliver a therapeutically effective amount of drug via the patients’ skin. Worldwide growing geriatric population along with rising in the prevalence of chronic diseases is the leading factor driving the market growth. In addition, rapid technological advancements in transdermal drug delivery systems and increasing adoption of third-generation delivery systems are expected to augment the market growth during the forecast period. The geriatric population is more prone to develop Q fever. The elderly population across the world is on the surge. The World Health Organization (WHO) reported that the worldwide population aged 60 years and above was 962.0 million in 2017, which is projected to increase to over 2.0 billion by 2050 and further would reach to 3.1 billion by 2100.
Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/7545
However, disadvantages of delivery systems including edema and irritation, natural limits of drug entry imposed by the skin’s impermeability, and lack of adhesion of the transdermal system to different skin types are anticipated to hinder the market growth over the forecast period. Additionally, drugs that require high blood levels cannot be administered through TDDS as it is limited only to potent molecules, those requiring a daily dose of 10 mg or less, thereby affecting the market growth.
The global transdermal (percutaneous) drug delivery systems market has been segmented into product, technology, application, and region.
By product, the market has been segmented into transdermal patches and transdermal semisolids. The transdermal patches segment is further categorized into drug-in-adhesive patches, matrix patches, reservoir membrane patches, and microneedle patches. The transdermal semisolids segment is additionally divided into gels, ointments, and sprays. The transdermal patches segment spearheaded the market in 2017 due to its benefits offered such as improved bioavailability, reduced dosing frequency, lower adverse events, enhanced patient compliance (non-invasive nature), painless application, and drug input termination at any point by the removal of the patch.
On the basis of technology, the market has been divided into electric current, iontophoresis, electroporation, ultrasound, microporation, thermal, and others.
Based on application, the market has been categorized into pain management, cardiovascular diseases, hormone replacement therapy, central nervous system disorders, smoking cessation, contraception, and others.
The global transdermal (percutaneous) drug delivery systems market has been segmented by region into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The transdermal (percutaneous) drug delivery systems market in the Americas has further been segmented into North America and Latin America, with the North American market divided into the US and Canada.
The European transdermal (percutaneous) drug delivery systems market has been segmented into Western Europe and Eastern Europe. The Western Europe transdermal (percutaneous) drug delivery systems market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The transdermal (percutaneous) drug delivery systems market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The transdermal (percutaneous) drug delivery systems market in the Middle East & Africa has been segmented into the Middle East and Africa.